Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in metastatic dMMR solid tumors
NCT04393454Phase 2Terminated
- Sponsor
- Albert Einstein College of Medicine
- Start
- Nov 2020
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in solid tumor, sponsored by Albert Einstein College of Medicine. Primary endpoint: Objective Response Rate at 24 weeks. Started Nov 2020; status: terminated.
02
Drugs
sirolimus
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04393454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393454.